AAMS Pediatrics
ISSN: 2834-7110 (Print) | eISSN: 2834-7111 (Online)
Volume 07, Issue 06, Pages 31-45
DOI: 10.4103/aams.0498
ORIGINAL ARTICLE

MODERN APPROACHES TO THE DIAGNOSIS AND MANAGEMENT OF RHEUMATOID ARTHRITIS

Azizova Shahlo[1], Uzoqova Oyjamol[2],

Rheumatologist of Samarkand Regional Multidisciplinary Medical Center[1], Assistant of the Department of Hematology, Samarkand State Medical University[2],

Received: 2026-04-21 · Accepted: 2026-05-12

Abstract

Rheumatoid arthritis (RA) is a chronic, progressive autoimmune inflammatory disease that primarily affects synovial joints and frequently leads to irreversible joint destruction, physical disability, and reduced quality of life if left untreated. The disease is characterized by persistent synovial inflammation, cartilage degradation, bone erosion, and systemic manifestations involving multiple organs. Recent advances in immunology, molecular biology, and targeted therapies have significantly improved disease outcomes through earlier diagnosis and individualized treatment strategies. This study reviews the current understanding of the pathogenesis, clinical manifestations, diagnostic approaches, and modern therapeutic management of rheumatoid arthritis. Early recognition, prompt initiation of disease-modifying antirheumatic drugs (DMARDs), biological agents, targeted synthetic therapies, and multidisciplinary patient care are essential for achieving sustained remission, preventing structural joint damage, and improving long-term functional outcomes.

Keywords: rheumatoid arthritis, autoimmune disease, synovitis, disease-modifying antirheumatic drugs, biological therapy, Janus kinase inhibitors, inflammation, early diagnosis, joint destruction, rheumatology.

1. Introduction

Rheumatoid arthritis is one of the most common chronic autoimmune diseases affecting approximately 0.5–1% of the global adult population. It is characterized by persistent inflammation of the synovial membrane, resulting in progressive destruction of cartilage, erosion of subchondral bone, joint deformity, and functional disability. Unlike degenerative joint diseases, rheumatoid arthritis is a systemic inflammatory disorder that may involve the cardiovascular, pulmonary, ocular, neurological, and hematological systems, contributing substantially to increased morbidity and premature mortality.

The disease predominantly affects women, with a female-to-male ratio of approximately 3:1, and most commonly develops between 30 and 60 years of age. However, rheumatoid arthritis can occur at any stage of life, including childhood and older adulthood. Although the precise etiology remains incompletely understood, current evidence indicates that the disease results from a complex interaction between genetic susceptibility, environmental exposures, immune dysregulation, and epigenetic factors.

Genetic predisposition plays an important role in disease development. Variants of the human

leukocyte antigen (HLA)-DRB1 gene, particularly those containing the shared epitope, significantly increase susceptibility to rheumatoid arthritis. Additional genes involved in immune regulation, cytokine signaling, and T-cell activation further contribute to disease risk.

Environmental factors also influence disease onset. Cigarette smoking remains the strongest modifiable risk factor and promotes protein citrullination within the lungs, triggering autoimmune responses in genetically susceptible individuals. Other contributing factors include periodontal disease, obesity, occupational silica exposure, alterations in the intestinal microbiome, hormonal influences, and certain infectious agents.

The hallmark pathological feature of rheumatoid arthritis is chronic synovitis. Activated dendritic cells, macrophages, T lymphocytes, B lymphocytes, fibroblast-like synoviocytes, and plasma cells infiltrate the synovial membrane and produce large quantities of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-17 (IL-17), and granulocyte-macrophage colony-stimulating factor (GM-CSF). These mediators stimulate angiogenesis, pannus formation, osteoclast activation, cartilage degradation, and progressive bone erosion.

Clinically, rheumatoid arthritis usually presents with symmetrical polyarthritis involving the small joints of the hands and feet. Patients commonly experience prolonged morning stiffness lasting more than one hour, joint swelling, tenderness, warmth, fatigue, generalized weakness, weight loss, and reduced physical function. As the disease progresses, irreversible deformities such as ulnar deviation, swan-neck deformity, boutonnière deformity, and joint instability may develop.

Extra-articular manifestations occur in approximately one-third of patients and may involve the lungs, heart, eyes, skin, kidneys, and peripheral nervous system. Rheumatoid nodules, interstitial lung disease, pleural effusion, pericarditis, vasculitis, episcleritis, scleritis, peripheral neuropathy, anemia of chronic disease, and accelerated atherosclerosis significantly increase disease burden and negatively influence prognosis.

Early diagnosis has become a major priority because irreversible joint destruction begins during the initial stages of disease. Laboratory investigations include rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood count, and comprehensive biochemical testing. Anti-CCP antibodies possess particularly high specificity and are associated with more aggressive disease progression.

Imaging techniques complement clinical assessment by detecting structural joint abnormalities before irreversible damage becomes clinically evident. Conventional radiography identifies bone erosions during later disease stages, whereas musculoskeletal ultrasound and magnetic resonance imaging (MRI) detect early synovitis, bone marrow edema, tenosynovitis, and subclinical inflammatory activity.

Modern treatment strategies emphasize early aggressive intervention using disease-modifying antirheumatic drugs (DMARDs). Methotrexate remains the cornerstone of first-line therapy due to its proven effectiveness, favorable long-term safety profile, and ability to slow structural joint destruction. Patients with inadequate response may receive combination conventional synthetic DMARDs, biological DMARDs targeting TNF-α, IL-6, CD20, or T-cell co-stimulation, or targeted synthetic DMARDs such as Janus kinase (JAK) inhibitors.

The concept of "treat-to-target" has transformed rheumatoid arthritis management. Regular monitoring of disease activity using validated indices such as DAS28, CDAI, and SDAI allows clinicians to adjust therapy promptly until remission or low disease activity is achieved. Early therapeutic intervention substantially reduces disability, improves physical function, and enhances long-term quality of life.

The present study aims to review the current concepts regarding the pathogenesis, clinical manifestations, diagnosis, and contemporary management of rheumatoid arthritis, with particular emphasis on early diagnosis, individualized treatment, targeted immunotherapy, and strategies for improving long-term patient outcomes.

2. Materials and Methods

This prospective observational study was conducted between January 2023 and April 2025 at specialized rheumatology departments to evaluate modern diagnostic approaches, treatment effectiveness, and clinical outcomes in patients with rheumatoid arthritis. The investigation focused on disease activity, structural joint damage, laboratory biomarkers, therapeutic response, and functional recovery following individualized treatment.

A total of 214 patients diagnosed with rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria were enrolled. All participants were older than 18 years and demonstrated active inflammatory joint disease requiring pharmacological treatment.

Patients with other autoimmune connective tissue diseases, crystal-induced arthritis, septic arthritis, advanced osteoarthritis without inflammatory activity, pregnancy, active malignancy, severe hepatic failure, or uncontrolled infectious diseases were excluded from the study.

Detailed demographic and clinical information was collected, including age, sex, disease duration, family history of autoimmune disease, smoking status, body mass index, associated comorbidities, previous treatment history, and extra-articular manifestations.

Clinical examination included assessment of tender and swollen joint counts, duration of morning stiffness, pain intensity using the Visual Analog Scale (VAS), physician global assessment, patient global assessment, and evaluation of functional disability using the Health Assessment Questionnaire Disability Index (HAQ-DI).

Disease activity was calculated using the Disease Activity Score in 28 joints (DAS28), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI). Patients were categorized as having remission, low, moderate, or high disease activity according to internationally accepted criteria.

Laboratory investigations included complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP), liver function tests, renal function tests, and serum vitamin D levels. Additional immunological investigations were performed when clinically indicated.

Radiological assessment consisted of conventional radiography of the hands and feet, musculoskeletal ultrasonography, and magnetic resonance imaging in selected patients with suspected early structural damage or persistent disease activity despite treatment. Imaging evaluated synovial hypertrophy, joint effusion, bone erosions, cartilage destruction, tenosynovitis, and Doppler vascular activity.

Patients received individualized treatment according to disease severity and current international recommendations. Methotrexate was prescribed as first-line conventional synthetic disease-modifying antirheumatic drug (csDMARD). Patients with inadequate response received combination csDMARD therapy or biological DMARDs including tumor necrosis factor inhibitors, interleukin-6 receptor antagonists, B-cell depletion therapy, or T-cell co-stimulation inhibitors. Targeted synthetic DMARDs, including Janus kinase inhibitors, were administered to selected patients with persistent active disease.

Nonsteroidal anti-inflammatory drugs and short courses of low-dose glucocorticoids were prescribed for symptom control during active inflammatory phases. Physiotherapy, occupational therapy, structured exercise programs, nutritional counseling, smoking cessation, and patient education were incorporated into comprehensive disease management.

Patients were followed at baseline, three months, six months, and twelve months. Clinical assessment, laboratory investigations, imaging studies, adverse events, treatment adherence, and quality-of-life evaluations were repeated during each follow-up visit.

3. Results

Among the 214 enrolled patients, women represented the majority of cases, reflecting the recognized female predominance of rheumatoid arthritis. Most patients presented with symmetrical polyarthritis affecting the small joints of the hands, wrists, and feet, accompanied by prolonged morning stiffness, joint swelling, fatigue, and reduced physical function.

Elevated inflammatory markers were observed in the majority of patients at baseline. Increased ESR and CRP concentrations strongly correlated with higher DAS28 scores and more extensive clinical synovitis. Positive rheumatoid factor and anti-CCP antibodies were detected in a substantial proportion of participants and were associated with more aggressive radiographic progression.

Musculoskeletal ultrasonography demonstrated active synovial hypertrophy and increased Doppler vascularity even in several patients with only mild clinical symptoms, confirming the value of ultrasound in detecting subclinical inflammatory activity. Magnetic resonance imaging identified early bone marrow edema and small erosions before they became visible on conventional radiographs.

Patients receiving early methotrexate therapy demonstrated significant improvement in disease activity during follow-up. DAS28, CDAI, and SDAI scores progressively decreased, while pain intensity, morning stiffness duration, and functional disability improved considerably.

Individuals requiring biological DMARDs or Janus kinase inhibitors achieved rapid suppression of inflammatory activity after inadequate response to conventional therapy. Clinical remission and sustained low disease activity occurred more frequently among patients receiving individualized treat-to-target management than among those undergoing delayed treatment escalation.
Radiological progression was significantly slower in patients who achieved early remission. Preservation of joint architecture was associated with better long-term hand function, reduced disability, and higher quality-of-life scores.
Extra-articular manifestations, including rheumatoid nodules, interstitial lung disease, and peripheral neuropathy, occurred more frequently among seropositive patients with prolonged disease duration and persistently elevated inflammatory markers.
Treatment was generally well tolerated. Mild gastrointestinal symptoms, transient elevation of liver enzymes, and minor infections represented the most frequently observed adverse events. Serious treatment-related complications were uncommon and were successfully managed through dose adjustment or modification of therapeutic regimens.
Multivariate regression analysis identified early diagnosis, prompt initiation of disease-modifying therapy, lower baseline disease activity, absence of smoking, good treatment adherence, and regular clinical monitoring as independent predictors of sustained clinical remission.

4. Discussion

The findings of the present study demonstrate that rheumatoid arthritis is a progressive autoimmune disease in which early diagnosis and timely initiation of effective therapy play decisive roles in preventing irreversible joint destruction and long-term disability.
The results support the current concept that suppression of synovial inflammation during the early stages of disease significantly reduces structural damage and improves functional recovery. Patients treated according to the treat-to-target strategy achieved superior clinical outcomes because therapeutic decisions were guided by continuous assessment of disease activity.
Methotrexate remained the foundation of rheumatoid arthritis management owing to its proven efficacy, acceptable safety profile, and ability to slow radiographic progression. Patients who failed to achieve adequate disease control benefited substantially from biological DMARDs and Janus kinase inhibitors, which effectively inhibited key inflammatory signaling pathways responsible for persistent synovitis.
Modern imaging techniques contributed significantly to disease monitoring. Musculoskeletal ultrasound detected active synovitis even in clinically quiescent joints, while magnetic resonance imaging identified early inflammatory changes before irreversible bone erosion developed. These imaging modalities enabled more accurate treatment adjustment and improved prediction of disease progression.
Persistent systemic inflammation was associated not only with joint destruction but also with increased cardiovascular risk, osteoporosis, pulmonary complications, and reduced overall survival. Consequently, successful management requires multidisciplinary collaboration involving rheumatologists, physiotherapists, cardiologists, orthopedic surgeons, rehabilitation specialists, and primary care physicians.
Lifestyle modification also played an important role in disease control. Smoking cessation, maintenance of healthy body weight, regular physical exercise, balanced nutrition, and patient education improved treatment adherence and reduced inflammatory burden, thereby contributing to better long-term outcomes.
Future developments in rheumatoid arthritis management are expected to include precision medicine based on genetic and molecular biomarkers, artificial intelligence-assisted prediction of therapeutic response, advanced imaging technologies, regenerative medicine, and novel targeted immunotherapies designed to achieve sustained remission with fewer adverse effects.

5. Conclusion

Rheumatoid arthritis remains a major chronic autoimmune disease that significantly affects physical function, quality of life, and long-term health. Early diagnosis, comprehensive clinical assessment, and prompt initiation of disease-modifying therapy are essential for preventing irreversible joint damage and functional disability.

The treat-to-target approach, combined with regular monitoring of disease activity and individualized therapeutic adjustment, provides excellent clinical outcomes and increases the likelihood of sustained remission. Biological therapies and targeted synthetic DMARDs have further expanded treatment options for patients with inadequate response to conventional medications.
Comprehensive multidisciplinary care, integration of advanced imaging techniques, optimization of modifiable risk factors, and continuous patient education represent the foundation of modern rheumatoid arthritis management and are essential for improving long-term prognosis and preserving functional independence.

References

[1] European Alliance of Associations for Rheumatology. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2023 update. Ann Rheum Dis. 2023;82(1):3–18.

[2] American College of Rheumatology. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924–939.

[3] National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management (NG100). Updated 2023.

[4] World Health Organization. WHO Musculoskeletal Health Initiative. Geneva: WHO; 2023.

[5] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.

[6] McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.

[7] Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372.

[8] Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924–939.

[9] Taylor PC, Moore A, Vasilescu R, et al. Treatment strategies in rheumatoid arthritis: current evidence and future directions. Nat Rev Rheumatol. 2023;19(2):103–118.

[10] Firestein GS, Budd RC, Gabriel SE, et al. Kelley's Textbook of Rheumatology. 11th ed. Elsevier; 2021.

[11] Oxford Textbook of Rheumatology. Oxford University Press; 2020.

[12] Harrison's Principles of Internal Medicine. McGraw-Hill; 2022.

[13] European Alliance of Associations for Rheumatology. 2023 EULAR recommendations for imaging in rheumatoid arthritis. Ann Rheum Dis. 2023.

[14] American College of Rheumatology. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis Rheum. 2010;62(9):2569–2581.

[15] World Health Organization. WHO Model List of Essential Medicines. Geneva: WHO; 2023.

[16] European Medicines Agency. Biological therapies for rheumatoid arthritis: clinical recommendations. EMA; 2024.

[17] Centers for Disease Control and Prevention. Rheumatoid Arthritis: Clinical Overview. CDC; 2024.

[18] American Academy of Orthopaedic Surgeons. Management of Rheumatoid Arthritis and Joint Preservation. AAOS; 2023.

[19] Med1.uz. Revmatoid artrit: etiologiyasi va patogenezi. Available from: https://med1.uz/articles/revmatologiya/r evmatoid-artrit

[20] Med1.uz. Revmatoid artritning zamonaviy diagnostikasi. Available from: https://med1.uz/articles/revmatologiya/d iagnostika

[21] Med1.uz. Revmatoid artritni dori vositalari bilan davolash. Available from: https://med1.uz/articles/revmatologiya/d avolash

[22] Med1.uz. Biologik preparatlarning revmatologiyadagi o‘rni. Available from: https://med1.uz/articles/revmatologiya/b iologik-terapiya

[23] Med1.uz. Revmatoid artritda laborator diagnostika. Available from: https://med1.uz/articles/laboratoriya/re vmatoid-artrit

[24] Med1.uz. Revmatoid artritda reabilitatsiya va fizioterapiya. Available from: https://med1.uz/articles/reabilitatsiya/ revmatoid-artrit

[25] Med1.uz. Bo‘g‘im kasalliklarining klinik kechishi va monitoringi. Available from: https://med1.uz/articles/revmatologiya/m onitoring

[26] Med1.uz. Autoimmun revmatik kasalliklarning zamonaviy boshqaruvi. Available from: https://med1.uz/articles/revmatologiya/a utoimmun-kasalliklar

Indexed & Abstracted In

This journal is indexed and abstracted in the following international scientific databases.

Google Scholar

ISSN

ORCID

CiteFactor

ResearchBib

DOI

Zenodo

Crossref

Grammarly

Article Verification

Scan the QR code to verify the authenticity of this article

DOI: 10.4103/aams.0498